Aktie KDST KADIMASTEM LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Kadimastem Ltd TEL AVIV STOCK EXCHANGE

Aktien

KDST

IL0011284614

KDST

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.
Kadimastem Plans Listing on Nasdaq Through Merger
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS
Kadimastem : Announces Executive Management Changes
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS
Kadimastem : Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14MQE Aktie
  4. KDST Aktie
  5. Nachrichten Kadimastem Ltd
  6. Andere Sprachen